KFS
NKTR icon

Kelly Financial Services’s Nektar Therapeutics NKTR Stock Holding History

Kelly Financial Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200
Closed -$53.9K – 698
2021
Q3 		$53.9K Buy
+200
New +$48.1K 0.03% 149

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Kelly Financial Services's NKTR Position: Q4 2021 in Review

Kelly Financial Services sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 200 shares — an estimated $53.9K sold.

Kelly Financial Services first reported a position in NKTR in Q3 2021 and held it in 1 quarter. The position peaked at $53.9K in Q3 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Kelly Financial Services reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Kelly Financial Services sold 200 Nektar Therapeutics shares in Q4 2021, an estimated $53.9K.
  • Kelly Financial Services first reported a position in Nektar Therapeutics in Q3 2021 and held it in 1 quarter.
  • Kelly Financial Services's Nektar Therapeutics position peaked at $53.9K in Q3 2021.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Kelly Financial Services's 13F filing for Q4 2021, filed 17 Jul 2024.